Document Classification

Section Type: RESULTS

Text: After 24 weeks, the zalcitabine-treated patients demonstrated significantly greater decreases in PHS scores (-4. 4 + / - 0. 6 ; saquinavir : -1. 3 + / - 0. 6 ; zalcitabine plus saquinavir : -1. 7 + / - 0. 6 ; P < 0. 0001) and MHS scores (-2. 2 + / - 0. 5 ; saquinavir : -1. 0 + / - 0. 5 ; zalcitabine plus saquinavir : -0. 5 + / - 0. 5 ; P = 0. 032) compared to saquinavir and zalcitabine plus saquinavir treated patients.